Percutaneous coronary intervention
|Percutaneous coronary intervention|
A coronary angiogram (an X-ray with radio-opaque contrast in the coronary arteries) that shows the left coronary circulation. The distal left main coronary artery (LMCA) is in the left upper quadrant of the image. Its main branches (also visible) are the left circumflex artery (LCX), which courses top-to-bottom initially and then toward the centre/bottom, and the left anterior descending (LAD) artery, which courses from left-to-right on the image and then courses down the middle of the image to project underneath of the distal LCX. The LAD, as is usual, has two large diagonal branches, which arise at the centre-top of the image and course toward the centre/right of the image.
Percutaneous coronary intervention (PCI), commonly known as coronary angioplasty or simply angioplasty, is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. These stenotic segments are due to the buildup of the cholesterol-laden plaques that form due to atherosclerosis. PCI is usually performed by an interventional cardiologist, though it was developed and originally performed by interventional radiologists.
During PCI, a cardiologist feeds a deflated balloon or other device on a catheter from the inguinal femoral artery or radial artery up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery.
Coronary artery bypass grafting (CABG), which bypasses stenotic arteries by grafting vessels from elsewhere in the body, is an alternative treatment. Most studies have found that CABG is better than PCI for reducing death and myocardial infarction. PCI has proven to be as effective and less costly than CABG in patients with medically refractory myocardial ischemia.
However,the coronary revascularization by CABG is associated with an increased risk of stroke.
Bare-metal stents (BMSs) and drug-eluting stents (DESs) result in an equivalent chance of death when used for primary angioplasty of ST elevation myocardial infarction. Cobalt-chromium stents which elute everolimus appear to clot off less often than other types of stents, including bare metal stents.
Coronary angioplasty is widely practiced and has a number of risks; however, major procedural complications are uncommon. Coronary angioplasty is usually performed using invasive catheter-based procedures by an interventional cardiologist, a medical doctor with special training in the treatment of the heart.
The patient is usually awake during angioplasty, and chest discomfort may be experienced during the procedure; the reporting of symptoms indicates the procedure is causing ischemia and the cardiologist may alter or abort part of the procedure. Bleeding from the insertion point in the groin (femoral artery) or wrist (radial artery) is common, in part due to the use of antiplatelet drugs. Some bruising is therefore to be expected, but occasionally a hematoma may form. This may delay hospital discharge as flow from the artery into the hematoma may continue (pseudoaneurysm) which requires surgical repair. Infection at the skin puncture site is rare and dissection (tearing) of the access blood vessel is uncommon. Allergic reaction to the contrast dye used is possible, but has been reduced with the newer agents. Deterioration of kidney function can occur in patients with pre-existing kidney disease, but kidney failure requiring dialysis is rare. Vascular access complications are less common and less serious when the procedure is performed via the radial artery.
The most serious risks are death, stroke, ventricular fibrillation (non-sustained ventricular tachycardia is common), myocardial infarction (heart attack, MI), and aortic dissection. A heart attack during or shortly after the procedure occurs in 0.3% of cases; this may require emergency coronary artery bypass surgery. Heart muscle injury characterized by elevated levels of CK-MB, troponin I, and troponin T may occur in up to 30% of all PCI procedures. Elevated enzymes have been associated with later clinical outcomes such as higher risk of death, subsequent MI, and need for repeat revascularization procedures. Angioplasty carried out shortly after an MI has a risk of causing a stroke, but this is less than the risk of a stroke following thrombolytic drug therapy.
As with any procedure involving the heart, complications can sometimes, though rarely, cause death. Less than 2% of people die during angioplasty. Sometimes chest pain can occur during angioplasty because the balloon briefly blocks off the blood supply to the heart. The risk of complications is higher in:
- People aged 75 and older
- People who have kidney disease or diabetes
- People who have poor pumping function in their hearts
- People who have extensive heart disease and blockages
The value of angioplasty in rescuing someone having a heart attack (by immediately alleviating an obstruction) is clearly defined in multiple studies, but studies have failed to find reduction in hard endpoints for angioplasty vs. medical therapy in stable angina patients. The artery-opening procedure alleviates chest pain far more quickly than medical therapy, but has not been shown to prolong life. The "vast majority of heart attacks do not originate with obstructions that narrow arteries".[dubious ]
The term balloon angioplasty is commonly used to describe percutaneous coronary intervention, which describes the inflation of a balloon within the coronary artery to crush the plaque into the walls of the artery. While balloon angioplasty is still done as a part of nearly all percutaneous coronary interventions, it is rarely the only procedure performed.
Other procedures done during a percutaneous coronary intervention include:
- Implantation of stents
- Rotational or laser atherectomy
- Brachytherapy (use of radioactive source to inhibit restenosis)
Sometimes, a small mesh tube, or "stent", is introduced into the blood vessel or artery to prop it open using percutaneous methods. Angioplasty with stenting is a viable alternative to heart surgery for some forms of non-severe coronary artery disease. It has consistently been shown to reduce symptoms due to coronary artery disease and to reduce cardiac ischemia, but has not been shown in large trials to reduce mortality due to coronary artery disease, except in patients being treated for a heart attack acutely (also called primary angioplasty). In acute cases, a small but definite reduction of mortality occurs with this form of treatment compared with medical therapy, which usually consists of the administration of thrombolytic ("clot busting") medication.
The angioplasty procedure usually consists of most of the following steps and is performed by physicians, physician assistants, nurse practitioners, nurses, radiological technologists, and cardiac invasive specialists; all of whom have extensive and specialized training in these types of procedures.
- Access into the femoral artery in the leg (or, less commonly, into the radial artery or brachial artery in the arm) is created by a device called an "introducer needle". This procedure is often termed percutaneous access.
- Once access into the artery is gained, a "sheath introducer" is placed in the opening to keep the artery open and control bleeding.
- Through this sheath, a long, flexible, soft plastic tube called a "guiding catheter" is pushed. The tip of the guiding catheter is placed at the mouth of the coronary artery. The guiding catheter also allows for radio-opaque dyes (usually iodine-based) to be injected into the coronary artery, so that the disease state and location can be readily assessed using real time X-ray visualization.
- During the X-ray visualization, the cardiologist estimates the size of the coronary artery and selects the type of balloon catheter and coronary guidewire that will be used during the case. Heparin (a "blood thinner" or medicine used to prevent the formation of clots) is given to maintain blood flow.
- The coronary guidewire, which is an extremely thin wire with a radio-opaque flexible tip, is inserted through the guiding catheter and into the coronary artery. While visualizing again by real-time X-ray imaging, the cardiologist guides the wire through the coronary artery to the site of the stenosis or blockage. The tip of the wire is then passed across the blockage. The cardiologist controls the movement and direction of the guidewire by gently manipulating the end that sits outside the patient through twisting of the guidewire.
- While the guidewire is in place, it now acts as the pathway to the stenosis. The tip of the angioplasty or balloon catheter is hollow and is then inserted at the back of the guidewire—thus the guidewire is now inside of the angioplasty catheter. The angioplasty catheter is gently pushed forward, until the deflated balloon is inside of the blockage.
- The balloon is then inflated, and it compresses the atheromatous plaque and stretches the artery wall to expand.
- If an expandable wire mesh tube (stent) was on the balloon, then the stent will be implanted (left behind) to support the new stretched open position of the artery from the inside.
Traditional ("bare-metal stent", BMS) coronary stents provide a mechanical framework that holds the artery wall open, preventing stenosis, or narrowing, of coronary arteries. In normal patients in the usual case, stenting during PCI for an ST elevation myocardial infarction (STEMI) in a hemodynamically stable patient is not recommended because evidence does not show a likelihood of positive outcome for this and does show increased mortality and complications. Medical societies therefore recommend against stent placement into a noninfarct artery during PCI. Percutaneous transluminal coronary angioplasty with stenting, when indicated, has been shown to be superior to angioplasty alone in patient outcome by keeping arteries patent for a longer period of time.
Newer drug-eluting stents (DES) are traditional stents coated with drugs, which, when placed in the artery, release certain drugs over time. These types of stents have been shown to help prevent restenosis of the artery through several different physiological mechanisms, which rely upon the suppression of tissue growth at the stent site and local modulation of the body's inflammatory and immune responses. Five drugs, umirolimus, zotarolimus, sirolimus, everolimus, and paclitaxel, have demonstrated safety and efficacy in this application in controlled clinical trials by stent device manufacturers. However, in 2006, three broad European trials seem to indicate that drug-eluting stents may be susceptible to an event known as "late stent thrombosis", where the blood-clotting inside the stent can occur one or more years stent implantation. Late stent thrombosis occurs in 0.9% of patients, and is extremely dangerous and is fatal in about one-third of cases when the thrombosis occurs. Newer generation DES products market a biodegradable coating which aims to reduce this risk. A more recent study proposes that, in the case of population with diabetes mellitus that are particularly at risk, a treatment with paclitaxel-eluting balloon followed by BMS may reduce the incidence of coronary restenosis or myocardial infarction compared with BMS administered alone.
When performing emergency PCI in a patient with an acute ST-elevation myocardial infarction, in addition to the arterial occlusion that caused the MI, multiple complex atherosclerotic plaques are commonly found in other coronary arteries. The PRAMI trial showed, in patients having emergency PCI for acute STEMI who also had significant multiple vessel disease, performing preventive PCI on non-infarct arteries reduced the risk of a composite endpoint of death from cardiac causes, nonfatal myocardial infarction and refractory angina significantly (relative risk 0.35).
Coronary angioplasty, also known as percutaneous transluminal coronary angioplasty (PTCA), because it is done through the skin and through the lumen of the artery, was first developed in 1977 by Andreas Gruentzig. The first procedure took place Friday Sept 16, 1977, at Zurich, Switzerland. Adoption of the procedure accelerated subsequent to Gruentzig's move to Emory University in the United States. Gruentzig's first fellow at Emory was Merril Knudtson, who, by 1981, had already introduced it to Calgary, Alberta, Canada. By the mid-1980s, many leading medical centers throughout the world were adopting the procedure as a treatment for coronary artery disease.
Angioplasty is sometimes erroneously referred to as "Dottering", after Interventional Radiologist, Dr Charles Theodore Dotter, who, together with Dr Melvin P. Judkins, first described angioplasty in 1964. As the range of procedures performed upon coronary artery lumens has widened, the name of the procedure has changed to percutaneous coronary intervention.
- Stroupe KT, Morrison DA, Hlatky MA, Barnett PG, Cao L, Lyttle C, Hynes DM, Henderson WG (September 2006). "Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients". Circulation 114 (12): 1251–1257. doi:10.1161/CIRCULATIONAHA.105.570838. PMID 16966588.
- Tullio Palmerini; Giuseppe Biondi-Zoccai; Letizia Bacchi Reggiani; Diego Sangiorgi; Laura Alessi; Stefano De Servi; Angelo Branzi; Gregg W. Stone,; Biondi-Zoccai; Reggiani; Sangiorgi; Alessi; De Servi; Branzi; Stone (August 2012). "Risk of Stroke With Coronary Artery Bypass Graft Surgery Compared With Percutaneous Coronary Intervention". Journal of the American College of Cardiology 60 (9): 798–805. doi:10.1016/j.jacc.2011.10.912. PMID 22917004.
- Kones, R (Sep 7, 2010). "Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.". Vascular health and risk management 6: 749–74. PMC 2941787. PMID 20859545.
- "JAMA Network | Archives of Internal Medicine | Drug-Eluting vs Bare-Metal Stents in Primary AngioplastyA Pooled Patient-Level Meta-analysis of Randomized Trials". Archinte.ama-assn.org. 2012-04-23. Retrieved 2012-11-08.
- Palmerini, T; Biondi-Zoccai, G, Riva, DD, Stettler, C, Sangiorgi, D, D'Ascenzo, F, Kimura, T, Briguori, C, Sabatè, M, Kim, HS, De Waha, A, Kedhi, E, Smits, PC, Kaiser, C, Sardella, G, Marullo, A, Kirtane, AJ, Leon, MB, Stone, GW (Mar 22, 2012). "Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.". Lancet 379 (9824): 1393–402. doi:10.1016/S0140-6736(12)60324-9. PMID 22445239.
- UK's NHS endorsed 'Best Treatments' advice on 'clinical evidence for patients from the BMJ' on Coronary angioplasty and its 
- Harold JG; Bass TA; Bashore TM et al. (May 2013). "ACCF/AHA/SCAI 2013 Update of the Clinical Competence Statement on Coronary Artery Interventional Procedures: A Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (Writing Committee to Revise the 2007 Clinical Competence Statement on Cardiac Interventional Procedures)". Circulation 128 (4): 436–72. doi:10.1161/CIR.0b013e318299cd8a. PMID 23658439.
- Jang JS; Jin HY; Seo JS et al. (August 2012). "The transradial versus the transfemoral approach for primary percutaneous coronary intervention in patients with acute myocardial infarction: a systematic review and meta-analysis". EuroIntervention 8 (4): 501–10. doi:10.4244/EIJV8I4A78. PMID 22581470.
- Yang EH, Gumina RJ, Lennon RJ, Holmes DR, Rihal CS, Singh (2005). "to 2003". Journal of the American College of Cardiology 46 (11): 2004–2009. doi:10.1016/j.jacc.2005.06.083. PMID 16325032.
- Califf R. M.; Abdelmeguid A. E. et al. (1998). "Myonecrosis after revascularization procedures". J Am Coll Cardiol 31 (2): 241–51. doi:10.1016/S0735-1097(97)00506-8. PMID 9462562.
- Tardiff B. E.; Califf R. M. et al. (1999). "Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II". J Am Coll Cardiol 33 (1): 88–96. doi:10.1016/S0735-1097(98)00551-8. PMID 9935014.
- Cucherat M, Bonnefoy E, Tremeau G (2003). "Primary angioplasty versus intravenous thrombolysis for acute myocardial infarction". Cochrane Database Syst Rev (3): CD001560. doi:10.1002/14651858.CD001560. PMID 12917910.
- "What Is Coronary Angioplasty? - NHLBI, NIH". Nhlbi.nih.gov. Retrieved 2012-11-08.
- Kolata, Gina. "New Heart Studies Question the Value Of Opening Arteries" The New York Times, March 21, 2004. Retrieved January 29, 2011.
- Michaels AD, Chatterjee K (December 2002). "Cardiology patient pages. Angioplasty versus bypass surgery for coronary artery disease". Circulation 106 (23): e187–90. doi:10.1161/01.CIR.0000044747.37349.64. PMID 12460885. Retrieved 2009-07-13.
- Mercado, N, Flather, MD, Boersna, E, et al., on Behalf of the Trial Investigators CABG vs Stenting for Multivessel Disease: a Meta-analysis of ARTS-1, SoS, ERACI-2, and MASS-2, Presentation at European Society of Cardiology Congress 2003
- Weaver WD; Simes RJ; Betriu A et al. (December 1997). "Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review". JAMA 278 (23): 2093–8. doi:10.1001/jama.278.23.2093. PMID 9403425.
- PTCA or Balloon Angioplasty
- American College of Cardiology. "Five Things Physicians and Patients Should Question". Choosing Wisely: an initiative of the ABIM Foundation (American College of Cardiology). Retrieved August 17, 2012
- Patel, M. R.; Dehmer, G. J.; Hirshfeld, J. W.; Smith, P. K.; Spertus, J. A. (2009). "ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization". Journal of the American College of Cardiology 53 (6): 530–553. doi:10.1016/j.jacc.2008.10.005. PMID 19195618.
- Gandhi MM, Dawkins KD (March 1999). "Fortnightly review: Intracoronary stents". BMJ (Clinical Research Ed.) 318 (7184): 650–3. doi:10.1136/bmj.318.7184.650. PMC 1115094. PMID 10066211.
- Windecker, Stephan; Serruys, Patrick W; Wandel, Simon; Buszman, Pawel; Trznadel, Stanislaw; Linke, Axel; Lenk, Karsten; Ischinger, Thomas; Klauss, Volker (2008). "Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial". The Lancet 372 (9644): 1163–1173. doi:10.1016/S0140-6736(08)61244-1.
- Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE (March 2007). "Stent thrombosis in randomized clinical trials of drug-eluting stents". The New England Journal of Medicine 356 (10): 1020–9. doi:10.1056/NEJMoa067731. PMID 17296821.
- European Society of Cardiology Science News, 2007 Thrombosis is the price for the success of drug-eluting stents
- Juan Mieres; Carlos Fernandez-Pereira; Gustavo Risau; Leonardo Solorzano; Ricardo Pauletto; Alfredo Matías Rodríguez-Granillo; Bibiana Rubilar; Pieter Stella; Alfredo E. Rodríguez (Sept–Oct 2012). "One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: Results from the DiabEtic Argentina Registry (DEAR)". Cardiovascular Revascularization Medicine 13 (5): 265–271. doi:10.1016/j.carrev.2012.06.001. PMID 22796496.
- Goldstein, J. A.; Demetriou, D.; Grines, C. L.; Pica, M.; Shoukfeh, M.; O'Neill, W. W. (2000). "Multiple Complex Coronary Plaques in Patients with Acute Myocardial Infarction". New England Journal of Medicine 343 (13): 915–922. doi:10.1056/NEJM200009283431303. PMID 11006367.
- Wald, D. S.; Morris, J. K.; Wald, N. J.; Chase, A. J.; Edwards, R. J.; Hughes, L. O.; Berry, C.; Oldroyd, K. G.; Prami, I. (2013). "Randomized Trial of Preventive Angioplasty in Myocardial Infarction". New England Journal of Medicine 369 (12): 1115–1123. doi:10.1056/NEJMoa1305520. PMID 23991625.
- Meier B, Bachmann D, Lüscher T (February 2003). "25 years of coronary angioplasty: almost a fairy tale". Lancet 361 (9356): 527. doi:10.1016/S0140-6736(03)12470-1. PMID 12583964.
- "Foothills Interventional Cardiology Service". Retrieved 2008-12-31.
- Dotter CT, Judkins MP (November 1964). "Transluminal treatment of arteriosclerotic obstruction". Circulation 30 (5): 654–70. doi:10.1161/01.CIR.30.5.654. PMID 14226164. Retrieved 2009-07-13.
Steve Stiles. Survey says: Most cardiologists support elective PCI sans on-site CABG. . . with caveats. theheart.org; Dec 13, 2011.
- Angioplasty.Org news and education
- European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- Q&A: Primary angioplasty, 18 Oct 2008
- Percutaneous Coronary Intervention - Patient UK
- Percutaneous Coronary Intervention - Medscape